BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Chubb
Fuji
Express Scripts
Cipla
QuintilesIMS
Cantor Fitzgerald
UBS
Teva

Generated: January 24, 2018

DrugPatentWatch Database Preview

RYTHMOL Drug Profile

« Back to Dashboard

Which patents cover Rythmol, and when can generic versions of Rythmol launch?

Rythmol is a drug marketed by Glaxosmithkline Llc and is included in two NDAs.

The generic ingredient in RYTHMOL is propafenone hydrochloride. There are eleven drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the propafenone hydrochloride profile page.
Drug patent expirations by year for RYTHMOL
Medical Subject Heading (MeSH) Categories for RYTHMOL

US Patents and Regulatory Information for RYTHMOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Llc RYTHMOL propafenone hydrochloride TABLET;ORAL 019151-001 Nov 27, 1989 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline Llc RYTHMOL SR propafenone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021416-001 Sep 4, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline Llc RYTHMOL propafenone hydrochloride TABLET;ORAL 019151-003 Nov 20, 1992 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline Llc RYTHMOL propafenone hydrochloride TABLET;ORAL 019151-002 Nov 27, 1989 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline Llc RYTHMOL SR propafenone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021416-003 Sep 4, 2003 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline Llc RYTHMOL SR propafenone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021416-002 Sep 4, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for RYTHMOL
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Capsules 325 mg ➤ Subscribe 11/7/2006
➤ Subscribe Extended-release Capsules 225 mg and 425 mg ➤ Subscribe 10/11/2006

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Fish and Richardson
Accenture
Johnson and Johnson
Dow
Moodys
Boehringer Ingelheim
Chinese Patent Office
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot